Zhejiang Hisun Pharmaceutical Co Ltd (600267) - Total Liabilities
Based on the latest financial reports, Zhejiang Hisun Pharmaceutical Co Ltd (600267) has total liabilities worth CN¥6.56 Billion CNY (≈ $960.28 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore cash flow conversion of Zhejiang Hisun Pharmaceutical Co Ltd to assess how effectively this company generates cash.
Zhejiang Hisun Pharmaceutical Co Ltd - Total Liabilities Trend (1997–2024)
This chart illustrates how Zhejiang Hisun Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Check 600267 asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Zhejiang Hisun Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Zhejiang Hisun Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Uniti Group Inc
NASDAQ:UNIT
|
USA | $11.40 Billion |
|
Shenzhen Rongda Photosensitive & Technology Co Ltd
SHE:300576
|
China | CN¥362.72 Million |
|
Costamare Inc
NYSE:CMRE
|
USA | $1.70 Billion |
|
Gansu Shangfeng Cement Co Ltd
SHE:000672
|
China | CN¥7.20 Billion |
|
Ourpalm
SHE:300315
|
China | CN¥410.75 Million |
|
ACME Solar Holdings Limited
NSE:ACMESOLAR
|
India | Rs156.42 Billion |
|
Shanghai Jahwa United Co Ltd
SHG:600315
|
China | CN¥3.42 Billion |
Liability Composition Analysis (1997–2024)
This chart breaks down Zhejiang Hisun Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of Zhejiang Hisun Pharmaceutical Co Ltd.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.95 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.77 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.43 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Zhejiang Hisun Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Zhejiang Hisun Pharmaceutical Co Ltd (1997–2024)
The table below shows the annual total liabilities of Zhejiang Hisun Pharmaceutical Co Ltd from 1997 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥7.39 Billion ≈ $1.08 Billion |
-20.19% |
| 2023-12-31 | CN¥9.26 Billion ≈ $1.36 Billion |
-11.33% |
| 2022-12-31 | CN¥10.45 Billion ≈ $1.53 Billion |
-13.14% |
| 2021-12-31 | CN¥12.03 Billion ≈ $1.76 Billion |
-4.56% |
| 2020-12-31 | CN¥12.60 Billion ≈ $1.84 Billion |
-8.56% |
| 2019-12-31 | CN¥13.78 Billion ≈ $2.02 Billion |
-4.78% |
| 2018-12-31 | CN¥14.48 Billion ≈ $2.12 Billion |
+5.19% |
| 2017-12-31 | CN¥13.76 Billion ≈ $2.01 Billion |
+8.19% |
| 2016-12-31 | CN¥12.72 Billion ≈ $1.86 Billion |
+15.53% |
| 2015-12-31 | CN¥11.01 Billion ≈ $1.61 Billion |
+21.87% |
| 2014-12-31 | CN¥9.03 Billion ≈ $1.32 Billion |
+12.72% |
| 2013-12-31 | CN¥8.01 Billion ≈ $1.17 Billion |
+49.20% |
| 2012-12-31 | CN¥5.37 Billion ≈ $786.00 Million |
+47.67% |
| 2011-12-31 | CN¥3.64 Billion ≈ $532.27 Million |
+14.48% |
| 2010-12-31 | CN¥3.18 Billion ≈ $464.96 Million |
+14.79% |
| 2009-12-31 | CN¥2.77 Billion ≈ $405.06 Million |
+7.62% |
| 2008-12-31 | CN¥2.57 Billion ≈ $376.38 Million |
+59.90% |
| 2007-12-31 | CN¥1.61 Billion ≈ $235.38 Million |
+4.30% |
| 2006-12-31 | CN¥1.54 Billion ≈ $225.67 Million |
+11.92% |
| 2005-12-31 | CN¥1.38 Billion ≈ $201.63 Million |
+40.92% |
| 2004-12-31 | CN¥977.76 Million ≈ $143.08 Million |
+12.13% |
| 2003-12-31 | CN¥871.96 Million ≈ $127.59 Million |
+16.15% |
| 2002-12-31 | CN¥750.69 Million ≈ $109.85 Million |
+45.84% |
| 2001-12-31 | CN¥514.75 Million ≈ $75.32 Million |
+14.64% |
| 2000-12-31 | CN¥449.01 Million ≈ $65.70 Million |
+6.34% |
| 1999-12-31 | CN¥422.24 Million ≈ $61.79 Million |
+47.02% |
| 1998-12-31 | CN¥287.20 Million ≈ $42.03 Million |
+70.26% |
| 1997-12-31 | CN¥168.68 Million ≈ $24.68 Million |
-- |
About Zhejiang Hisun Pharmaceutical Co Ltd
Zhejiang Hisun Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of biological and generic drugs in China. The company provides active pharmaceutical ingredients and finished dosage form products. It offers products for anti-tumor, anti-infection, cardiovascular, endocrine, immunosuppression, antidepressant, liver care, and orthopaedics treatment; and weight loss… Read more